11th CAR-TCR Summit

Memo

Advancing the Development of Targeted, Scalable Cell Therapies through Disruptive Ex Vivo and In Vivo Technologies, Automated Manufacturing and Strategic Partnerships to Safeguard the Commercial Success of the IndustryThe cell therapy field is entering a more demanding phase, with focus shifting from early momentum to long-term commercial success. Attention is turning to novel innovations like in vivo therapies and automated manufacturing: two game-changing strategies that promise to cut costs, speed up development, and unlock commercial viability. With more than $6.6 billion invested in the last six months from the likes of AbbVie and Kite, investor confidence is returning, but with clear expectations. It’s critical to adapt to this next wave of innovation where standout clinical data and scalable platforms are non-negotiable. The 11th CAR-TCR Summit is your must attend forum, bringing together the latest scientific innovation across therapeutic classes and indications to inform your business strategy and support long term commercial success. Renowned for its caliber of networking and unparalleled depth of content, expect cutting-edge clinical data on ex vivo and in vivo advances, clinical trial strategies to support expanded patient access across indications, scalable and automated manufacturing processes to improve speed and costs, as well as commercial reflections to learn from those on the market. URLs:Tickets: https://go.evvnt.com/3615112-2?pid=5569Brochure: https://go.evvnt.com/3615112-3?pid=5569 Date and Time: On Tue, 15 Sep 2026 08:00 - Thu, 17 Sep 2026 18:00 Venue Details: The Westin Boston Seaport District, 425 Summer Street, Boston, Massachusetts, 02210, United States Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Clinical Prices:Drug Developer Pricing - Full Access Pass: Conference + Fundamentals Day or In Vivo Day or Automation Day or Partnering Day: USD 4397.00,Drug Developer Pricing - Conference Only: USD 3099.00,Academic and Small Scale Biotech Pricing - Full Access Pass: Conference + Fundamentals Day or In Vivo Day or Automation Day or Partnering Day: USD 3797.00,Academic and Small Scale Biotech Pricing - Conference Only: USD 2699.00,Service Provider Pricing - Full Access Pass: Conference + Fundamentals Day or In Vivo Day or Automation Day or Partnering Day: USD 6577.00,Service Provider Pricing - Conference Only: USD 5279.00 Speakers: Patrick Rivers, Portfolio Manager, AMoon Fund, Koji Yasuda, Principal, Fast Track Initiative Inc, Ilya Yasny, Managing Partner, Lance Bio Ventures, Randy Berholtz, Senior Advisor, Mesa Verde Venture Partners, Bill Querbes, Chief Scientific Officer, Aera Therapeutics, Inc, Sidharth Kerkar, Founder and Chief Executive Officer, AllerGene AI, Luke Pase, Chief Technology Officer, Anocca AB, Matthias Will, Chief Development Officer, Autolus, Robert Keefe, Chief Technology Officer, BlueSphere Bio, Samik Basu, Chief Scientific Officer, Cabaletta Bio, Felix Lorenz, Co-founder, Chief Executive and Scientific Officer, Captain T Cell, Ali Soleymannezhad, Chief Commercial Officer, Cellares Corporation, Adrian Kilcoyne, Chief Medical Officer, Cellectis, Greg Russotti, Technology Chief and Manufacturing Officer, Century Therapeutics, Tom Wickham, Chief Scientific Officer, GentiBio, Yongke Zhang, Chief Scientific Officer, IASO Biotherapeutics, John Byon, Chief Medical Officer, Imugene, Jan Davidson, Chief Medical Officer, Imviva Biotech, Shawn He, Chief Scientific Officer, JW Therapeutics, Aaron Edwards, Co-Founder and Chief Executive Officer, KiraGen Bio, Mark Exley, Chief Scientific Officer, LIfT BioSciences Ltd, Mark Wallet, Chief Scientific Officer, Link Cell Therapies, Nan Zhang, Cell Therapy Manufacturing Section, Center For Cellular Engineering, NIH Clinical Center Chief, National Institute of Health Science, Raphael G. Ognar, President, Chief Executive Officer and Co-Founder, NKILT Therapeutics, Ed Zhang, Co-Founder and Chief Executive Officer, Overland Pharmaceuticals, Rachel Abbott, Chief Executive Officer, Pan Cancer T, Tim Gallagher, Chief Operating Officer, PhosphoGam, Daniel Shelly, Chief Business Development Officer, PolTREG, Helen Sabzevari, President and Chief Executive Officer, Precigen, Kanya Rajangam, President, Chief Medical Officer and Head of Research and Development, Senti Biosciences Inc., Peggy Sotiropoulou, Chief Scientific Officer, T-knife GmbH, Leonardo Ferreira, Founder and Chief Executive Officer, Torpedo Bio, Nikhil Mutyal, Global Head of Search and Evaluation, Respiratory and Immunology, AstraZeneca, Serena De Vita, Vice President, Global Franchise Head and Clinical Strategy Head, Late Development Oncology, Cell Therapy, ORD, AstraZeneca, Callum Chapman, Head of Global Product Quality Biologics, AstraZeneca, Ruth Salmon, Vice President, Preclinical Sciences, Bristol Myers Squibb, Seraphin Kuate, Director, Global CMC Regulatory, CAR T Cell Therapy, Bristol Myers Squibb, Stephan Krause, Executive Director, Analytical Science , Technology and Cell Therapy Quality, Bristol Myers Squibb, Vaishali Shukla, Vice President, CGT and API Global Expansion, Eli Lilly and Co., Hong Xin, Senior Director, Oncology Scientific Innovation, Johnson and Johnson, Vicki Plaks, Senior Director, Scientific Head of Cell Therapy Oncology, Translational Research, Johnson and Johnson, Lana Shiu, Vice President, Global Regulatory Affairs, Kite Pharma Inc, Jose Caraballo, Vice President Quality, Kite Pharma Inc, Chris Crowell, Global Head of Manufacturing, Kite Pharma Inc, Balazs Csoka, Director and Head of Quality Control, Analytical Science and Technology, Novartis, Xiaodong Zhang, Director, Search and Evaluation, Oncology and Hematology, Novartis AG, Yu Qian, Head Director, Analytical Project Leads, Cell Therapies, Novartis AG, Russell Goetze, Director, Analytical Development, Regeneron Pharmaceuticals, Aaron Cooper, Vice President, Early Discovery, Arsenal Biosciences, Inc., Yan Li, Senior Director, Process Development, Manufacturing Science and Technology, Cabaletta Bio, Enrique Zudaire, Senior Vice President, Translational Sciences and Therapeutics Discovery, Caribou Biosciences, Justin Skoble, Vice President, Technical Operations, Caribou Biosciences, Matthias Bozza, Director, Research and Development Head of Strategy, CPTx, Pei Wang, Senior Vice President, Clinical Development and CMC, Eureka Therapeutics, Natalie Shiff, Senior Medical Director, Fate Therapeutics, Karine Pozo, Associate Director, Program Management, Immatics Gmbh, Emad Abdelnaby, Senior Vice President, Head of Commercial, Legend Biotech, E-Ching Ong, Associate Director, Process Development, Lyell Immunopharma, Michael Mingueneau, Vice President, Immunology, Sail Biomedicines, Lyndsey Young, Executive Director, Quality, Tr1x therapeutics, Samantha O’Hara, Director, Product Sciences, Umoja Biopharma, Luke Russell, Executive Vice President, Vyriad, Chupei Zhang, Director, Head of MSAT, Wugen Inc., Shon Green, Co-Founder, Zelig Tx, Sharon Anderson, Vice President, Scientific Affairs, Alliance for Regenerative Medicine, Rudolph Hulspas, Dana-Farber Cancer Institute, Xiuyan Wang, Director, Biotherapeutics Core Facility, Memorial Sloan Kettering Cancer Center, Kingyin Lee, Head of Clinical Trials, MHRA, Lavakumar Karyampudi, Senior Director, Cell Therapies, Moffitt Cancer Center, Steven Feldman, Site Head and Scientific Director, Laboratory for Cell and Gene Medicine, Stanford GMP Facility, Bruce Levine, Barbara and Edwad Netter Professor in Cancer Gene Therapy, University of Pennsylvania, Safia Abdi, Lead Research Analyst, Beacon, Jessie Ni, VP of Product Development, BioLegend, John Cesarek, Senior Director, Automation Engineering, Cellares Corporation